OK so you thought the title of the other thread was out of date BUT unfortunately there is no way to edit thread titles.

So here is a new title

This one has got the charts at the top again & has a link to the old one.
http://www.moneyam.com/InvestorsRoom/posts.php?tid=5021

Still watching & waiting.

I can`t belive no people have been here today.

Yep drifting down until next news or rumour.

Is it all based on rumour,surely not apple.

No, it's only a rumour that some of it is based on rumour. LOL

I'm confident that OXB will hit the bigtime someday, I just don't know when.

Until then, it is profitable to trade it, IF you get your timing right :-)

I will wait for my price,keep the faith.

daves dazzlers

Yep, 16p is probably the price to buy again.

Still got some though, I didn't sell them all just in case.

15,if you want to make money,i can wait.

Be strong!!

15p eh?

You may be right but a good RNS could arrive at any time & scupper our plans.

On the other hand, anybody want to set a target of 14p?

We were down at 14p recently.

Now that would be the cream,,sorry dream !

There`s a real case of stalking oxb for me .

I sold my original stake at 19p on Monday, looking to get back in around 16p. IMHO this stock has great potential but is news driven. Keep on your watchlists and pounce when you think the timing is right.

Sold at 19.63 and placed money into BPRG for time being and so far so good. Make on BPRG short term, sell and wait for OXB too hit another entrance point.
However as pointed out regards OXB any good RNS and bang goes that plan!!
Good luck all

OXFORD BIOMEDICA AND ARIUS RESEARCH EXTEND COLLABORATION ON NOVEL CANCER TARGETS

Success of initial stage leads to further two-year partnership

Oxford BioMedica (LSE: OXB) and ARIUS Research Inc. (TSX-VE: ARI) announced today the first milestone and their decision to move into the next phase of their collaboration to discover and characterise novel cancer targets and downstream therapeutic products. Under the agreement, antigen targets and antibodies can be out-licensed to commercial partners or developed by one or both of the companies.

In the initial phase of the collaboration, which began on 25 July 2002, 50 functional anti-cancer antibodies from the ARIUS library were used by Oxford BioMedica to mine for novel targets. The decision to extend the collaboration comes from the successful identification of three targets that offer opportunities in a range of cancer diseases. The new collaboration will focus on one that is over-expressed in gastrointestinal and other cancers and is related to cancer metastasis.

The success of the initial phase is due to synergies between the two companies. ARIUS FunctionFIRST discovery platform starts with human tumour cells and selects for antibodies with direct anti-cancer effects. By not starting from a known target, the ARIUS platform offers opportunities to discover novel targets or the unique spots on a target that are important in triggering cancer cell death. Oxford BioMedica has a number of proprietary technologies from its gene discovery and immunotherapy programmes and has both the technical skills to develop products and the business development experience to market them.

ARIUS' President and CSO, Dr. David Young said: "Our ongoing relationship with Oxford BioMedica has the potential to deliver significant value as we move to commercialise these discoveries. Oxford BioMedica has been an excellent partner and has made an important contribution to developing these library candidates."

http://www.oxfordbiomedica.co.uk/news/2004-ob-19.htm

Thank you Janus - any view on why this does not merit RNS

There actually was an RNS Number:6130E but for some reason it wasnt picked up on all news services.

Thanks again - I am limited to picking up news from MoneyAM Stockwatch obviously on the stock I hold. How did you get hold of RNS 6130?

Normally I use
http://www.uk-wire.com/ but that wasnt picked up this morning on there. It was on ADVFN though http://www.advfn.com/p.php?pid=news&epic=OXB&cb=1099057225

:-)

Just as I said, an RNS would scupper my plan to buy some more at 16p.

i see one of the brokers, (can't remember which) has put a 45p target on these.